methyl N-[(2S)-1-[(2S)-2-[5-fluoro-4-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate | 1373165-57-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(2S)-1-[(2S)-2-[5-fluoro-4-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• CAS: 1373165-57-1
• 化学式: C₄₀H₄₉FN₈O₆
• 分子量: 756.877
• InChiKey: XRJMEFUNEADJCZ-YDPTYEFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  55
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  、 MOC-L-缬氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 反应 15.0h， 生成 methyl N-[(2S)-1-[(2S)-2-[5-fluoro-4-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
  参考文献：
  名称：

  Synthesis and evaluation of novel potent HCV NS5A inhibitors

  摘要：

  Judicious modifications to the structure of the previously reported HCV NS5A inhibitor 1, resulted in more potent anti-HCV compounds with similar and in some cases improved toxicity profiles. The synthesis of 19 new NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. For the most potent compounds chemical stability, stability in liver microsomes and inhibition of relevant CYP450 enzymes is also presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.039

文献信息

• POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
  申请人：RFS Pharma, LLC.

  公开号：EP2963034A1

  公开（公告）日：2016-01-06

  The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

  本发明涉及用于治疗或预防人类或其他动物宿主感染丙型肝炎病毒（HCV）的化合物、组合物和方法。这些化合物也是药学上可接受的盐类、原药及其他衍生物，可作为治疗或预防 HCV 感染的药物组合物和方法。